Comments
Cadila Healthcare (Zydus Cadila) on Friday informed that the company has recieved the final approval from the US drug regulator, USFDA to market Carboplatin Injection, 10 mg/ml in 5 ml, 15 ml and 45 ml.
The group now has more than 100 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04, a company statement said here.
Cadila Healthcare shares gained 1.3 per cent on Bombay Stock Exchanfe to trade at Rs 321.35 after touching a low if Rs 313.30 in early trades.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.